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Abstract
Background: Warfarin is a commonly used anticoagulant. Whether a given dose of the different formulations of
Brazilian warfarin will result in the same effect on the international normalized ratio (INR) is uncertain. The aim of
the WARFA trial is to determine whether the branded and two generic warfarins available in Brazil differ in their
effect on the INR.
Methods: WARFA is a cross-over RCT comparing three warfarins. The formulations tested are the branded Marevan®
(Uniao Quimica/Farmoquimica) and two generic warfarin (manufactured respectively by Uniao Quimica
Farmaceutica Nacional and Laboratorio Teuto Brasileiro). All of them were manufactured in Brazil, are available in all
settings of the Brazilian healthcare system and were purchased from retail drugstores. Eligible participants had atrial
fibrillation or flutter, had been using warfarin for at least 2 months with a therapeutic range of 2.0–3.0 and had low
variability in INR results during the 1st period of the trial. Our primary outcome, for which we have an equality
hypothesis, is the difference between warfarins in the mean absolute difference between two INR results, obtained
after three and 4 weeks with each drug. Our secondary outcomes, that will be tested for inequality (except for the
mean INR, which will be tested for equality), include the difference in the warfarin dose, and time in therapeutic
range. Clinical events and adherence were also recorded and will be reported.
Discussion: To our knowledge, WARFA will be the first comparison of the more readily applicable INR results
between branded and generic warfarins in Brazil. WARFA is important because warfarins are commonly switched
between in the course of a chronic treatment in Brazil. Final results of WARFA are expected in May 2017.
Trial registration: ClinicalTrials.gov NCT02017197 . Registered 11 December 2013.
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Background
Novel drugs’ efficacy and safety must be proven by ran-
domized clinical trials (RCTs). Generic drugs, however,
follow different regulations and instead, are required to
demonstrate their similarity to the branded product,
already proven efficacious and safe [1].
There are different criteria on how to prove similarity
depending on the pharmaceutical product and on the
active pharmaceutical ingredient. Generally, for generic
drugs in solid oral dosage formulations (e.g. tablets), bio-
equivalence studies are a requisite [2–4]. These studies
assess whether the amount of drug absorbed and the
rate of absorption between the generic and the branded
drug do not show differences greater than prespecified
limits [2]. In Brazil all bioequivalence claims must still
show evidence that the 90% confidence interval (CI) of
the difference or of the ratio between the means of the
generic and the branded drug comply with the limits of
+20% and −20% of the branded drug mean1 [5, 6],
whereas a recent guideline set narrower limits for low
therapeutic index drugs [2].
There is debate on whether generic warfarin is really
equivalent to the branded drug [7–13]: first because this
is a drug with a narrow therapeutic index [14, 15], whose
effects must be strictly controlled in order to balance
benefits and risk; moreover, because generic drugs’
effects are not routinely assessed in randomized con-
trolled trials (only surrogate bioequivalence outcomes).
Consequently, potentially wide equivalence intervals for
generic drugs may result in excessive variation in the
effects of warfarin that lead to suboptimal anticoagula-
tion or the need for additional monitoring.
This question has been addressed before with RCTs [9–
13] but, to our knowledge, never with drugs manufactured
in Brazil. Therefore, they may not be applicable to the
Brazilian setting, since bioequivalence, which relies on
bioavailability, is highly dependent on the formulation and
manufacturing of the drug. Also, in Brazil, an even more
relevant question is whether there is equivalence also
within the generics since it is usual for patients in their
chronic treatment to receive, from hospitals (either public
or private) or from other public healthcare settings, the
same drug manufactured by different laboratories.
The aim of the WARFA trial is to compare the branded
(Marevan®) with two generic warfarins available in Brazil
for therapeutic equivalence. This paper describes the
design of the trial and our analysis plan.
Methods
Study design and setting
WARFA is a single-centre cross-over RCT. The trial
features 3-drugs, 4-periods (1 month each), 6-sequences
and is depicted in Table 1. The allocation ratio to each
sequence is 1:1:1:1:1:1. A populated SPIRIT (Standard
Protocol Items: Recommendations For Interventional
Trials) checklist is provided as the Additional file 1.
Patient recruitment started in August 2014 and was
finished by March 2016; follow-up was concluded by
August 2016. Patients were selected from the outpatient
anticoagulation clinic at the Hospital Sao Paulo, a public
university hospital in the city of Sao Paulo (Sao Paulo
State, Brazil).
Ethics approval, consent to participate and trial
registration
Ethical approval has been received from the research
ethics committee at the Federal University of São Paulo
(CAAE 20758713.3.0000.5505). All patients signed the
consent form prior to inclusion in the trial. The trial was
registered at ClinicalTrials.gov (NCT02017197) on 11
Dec 2013, before the inclusion of the first patient.
Study population
The eligibility criteria were designed to select a subset of
homogeneous patients that received warfarin and for
whom warfarin is indicated and safe. Eligible patients had
to meet all the following criteria: age ≥ 18 years; atrial
fibrillation (AF) (permanent, persistent or paroxysmal, but
not transient AF) diagnosed by physicians in the absence
of a mechanical valve and documented with electrocardio-
gram results; CHA2DS2VASc score ≥ 1 [16, 17]; on
warfarin for at least 2 months prior to randomisation; able
to provide written informed consent to participate.
Patients with any of the following exclusion criteria were
not eligible: patients for whom warfarin was con-
traindicated (e.g. use of another anticoagulant, recent
significant bleeding, known sensitivity to warfarin); preg-
nant, breastfeeding or women of childbearing potential;
severe thrombocytopenia (<40,000/μL); advanced hepatic
(i.e. liver cirrhosis) or renal failure (eGFR <15 mL/min/
1.73m2); history of major bleedings due to congenital
deficiency of coagulation factors; participating in another
clinical trial; patients starting chronic treatment with
drugs that have moderate and/or major interactions that
Table 1 Schema for the cross-over design of the study
Periodsa Period 1 Period 2 Period 3 Period 4
Sequences
AABC A A B C
BBAC B B A C
BBCA B B C A
AACB A A C B
CCAB C C A B
CCBA C C B A
B Branded warfarin, A and C, Generic formulations of warfarin, each from a
different manufacturer
aEach period is one-month long
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might affect the INR, and/or the warfarin dose, and/or the
risk of bleeding when used concurrent with warfarin (ac-
cording to the online database Micromedex® 2.0 [18]).
After randomization, only patients with low variability
of their INR results during the first 4 week period
continued in the study. Patients were kept in the study if
at least one of the three (including the baseline) INR
results were between 2.0 and 3.0 and the difference of
INR results at the 3th and 4th week ≤ ±0.8. This
decision was made to reduce the amount of variability in
INR values created by non-drug sources (e.g. patients
with variable vitamin K intake) and therefore increase
the probability of detecting true between drug
differences in INR.
Interventions and controls
Patients received three different formulations of warfarin
sodium tablets, one in each period, according to the
sequences to what they were randomized. The branded
one was Marevan®, from Uniao Quimica/Farmoquimica,
and the other two were generics manufactured respect-
ively by Uniao Quimica Farmaceutica Nacional and
Laboratorio Teuto Brasileiro [19]. All of them were
manufactured in Brazil and are available in all settings of
the Brazilian healthcare system (both public and private).
The drugs used in the trial were purchased from a retail
drugstore, not directly from the manufacturers, to
enhance the comparability of the trial results to “real-
world” conditions.
Patients were oriented to take the warfarin 5 mg tab-
lets (the most widely available dose form) once a day, at
the same time each day. If needed for their daily dose,
patients would split the tablets to receive 2.5 mg dose
increments/decrements. Study visits were planned in the
3rd and 4th week after starting every different warfarin;
at each visit, if necessary, warfarin dosage was adjusted
to keep the INR results within the therapeutic range of
2.0 to 3.0.
Adjustment of the warfarin dose followed an adapted
version of the ENGAGE AF-TIMI 48 trial protocol for
dose adjustment (Additional file 2) [20]. The criteria de-
scribed in the guideline was applied if at least two con-
secutive INR results were out of range. Exceptions were
when INR results were <1.5 or else >3.5: in these cases,
a single INR result out of range could motivate adding
extra doses or else suspending subsequent warfarin
doses. When INRs were out of range extra visits could
be scheduled for monitoring INR results and adjusting
warfarin dosage.
Concomitant medication was allowed. All patients
were instructed to: take their other drugs (for other
chronic or acute conditions) as instructed by their physi-
cians; avoid self-medication (patients were advised to
avoid nonsteroidal anti-inflammatory drugs (NSAIDs)
and use the over-the-counter acetaminophen or dypir-
one if needed for minor occasional pain, due to their
low potential for interaction with warfarin); and report
all new drugs (i.e., a drug that he/she had not been tak-
ing since baseline) to the investigator.
At the study visits the investigator inquired and regis-
tered concomitant medications. Before the analysis,
INRs will be classified as valid or invalid. We will con-
sider INRs valid if the measurements due were taken
when the patient was using the drug to which he/she
was assigned without interference of current diarrhoea.
We will consider INR measurements as invalid if they
were collected: 1) when a new drug with major or mod-
erate interactions was used in the last 24 h along with
warfarin (for drugs with moderate interactions, they also
had to be used on a continuous basis or at least more
than once in the last 24 h); 2) after suspension of a drug
with moderate or major interactions previously taken
since baseline. We only considered interactions that, ac-
cording to Micromedex® 2.0 [18], might alter the INR,
and/or the warfarin dose, and/or the risk of bleeding.
Treatment with warfarin had to be suspended in the
following situations: for a limited and short time if pa-
tients had to be submitted to specific surgical interven-
tions, as recommended by the American College of
Chest Physicians [21]; or else in the case of major bleed-
ing. In the latter, treatment was not resumed until the
source of the bleeding was identified and we were sure
that the patient would be more benefitted than harmed
by the treatment.
Compliance was measured by pill count at the end of
each period. Though INR figures as an outcome, it was
also used, coupled with pill count, as an ancillary meas-
ure of adherence. Feedback was given to patients as a
way of ensuring adherence.
Outcomes
For planning the outcomes, our concern was to address
two possible situations: 1) tablets within a manufacturer
could have varying doses or bioavailabilities due to inad-
equate quality control; 2) between manufacturers, tablets
could have consistently dissimilar bioavailability (e.g. one
formulation with a high bioavailability in comparison to
the others). Both situations could pose risks to the pa-
tient by placing them out of the therapeutic range [22]
and/or incur in the need for more consultations for dose
adjustment.
To reflect these potential situations, our primary out-
come is the difference in Δ INR. The Δ INR is the abso-
lute difference between the two INR results obtained by
the patient with the same drug formulation at each
period (Table 2). This measurement is intended to ad-
dress variation in the INR results. We have an equiva-
lence hypothesis and we will accept the warfarins as
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therapeutic equivalent if the 95% CI (lower and upper
bounds) of the difference between the mean Δ INR of
the formulations is within −0.49 and +0.49. The bounds
for the equivalence test were determined by consensus
with a cardiologist experienced in warfarin management
as the minimal important difference in the INR results
that would support a dose change.
This equivalence interval was intended originally for
the outcome of the difference between mean INRs, our
original primary outcome, but we thought it was suitable
for this new primary outcome as well. We made this
change to the protocol because we felt that, for being an
average between only two measurements, the mean INR
would not be sensitive enough to identify important var-
iations in INR results between treatments. Thus we re-
placed the mean INR (that turned to a secondary
outcome) by the Δ INR as the primary outcome.
The difference between mean INRs for each formu-
lation is one of the secondary outcomes for which we
also have an equivalence hypothesis using exactly the
same criteria (equivalence interval within −0.49 and
+0.49 and decision based on the 95% CI for the dif-
ference of the mean INRs fitting entirely into it). Dif-
ferently from the primary outcome, this measurement
is intended to address systematically lower or higher
mean INR results.
For the other secondary outcomes we have inequality
hypothesis. They are: the difference between mean war-
farin dosage needed, the difference between Δ warfarin
dosage needed (the absolute difference between the two
weekly warfarin dosages needed by the patient with the
same drug formulation at each period) and the differ-
ence between mean time in therapeutic range (TTR).
Clinical events (thromboembolic, bleeding events, deaths
and other adverse effects) were also recorded and we
will present their frequencies, but we will not conduct
hypothesis tests because these were not the main out-
comes in this trial and we were very likely underpowered
for detecting differences between treatments; also, the
cross-over design was not suitable for assessing these
kind of outcomes since most of them would lead to sus-
pension of the warfarin treatment for indeterminate
time, making it impossible for the patient to be exposed
to the next interventions in the sequence. The adherence
with treatment was also measured and we will present it
in a dichotomous way (e.g. patients had at least 80%
adherence).
A secondary outcome that was planned at the begin-
ning but we have discarded for the final analysis is the
difference between mean prothrombin times (PTs). The
PT is the basis for the INR, which was created to ad-
dress the problem of comparability of laboratory results
Table 2 Schedule of enrolment, interventions, and assessments of the WARFA trial
STUDY FOLLOW-UP
Enrolment/
Randomization
1st Month/
Period
2nd Month/
Period
3rd Month/
Period
4th Month/
Period
WEEK 0 3 4 7 8 11 12 15 16
ENROLMENT
Eligibility screen X
Informed consent X
Allocation X
INTERVENTIONS
Assessment of INR variability X
Switch of warfarin formulation X X X
ASSESSMENTS
Assessment of patient stability in warfarin treatment X
INR X X X X X X X X X
PT X X X X X X X X X
Warfarin dosage X X X X X X X X X
Stroke X X X X X X X X X
Major Bleeding X X X X X X X X X
Death X X X X X X X X X
Systemic thromboembolism X X X X X X X X X
Minor bleeding X X X X X X X X X
Adherence X X X X
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[23] and it is a measure widely used nowadays. Thus we
decided that analyzing the PT in addition to the INR
would be unnecessary since it would convey the same
information as the INR.
INR, warfarin dosage, and clinical events will be mea-
sured at the study visits in the 3rd and 4th week of each
period. The outcomes of Δ INR, mean INR, Δ dosage,
mean dosage and mean TTR will also be based on these
measurements. Adherence will be measured in the 4th
week of each period.
The controls for each intervention will vary according
to the comparison being made: when comparing the
generic formulations to the branded we will use the lat-
ter as the control; when comparing generics to each
other, we will use always the same generic formulation
as the control for the other.
Randomization and blinding
We applied block randomization (fixed block size of 6).
Patients were randomly allocated to the sequences of
treatment by numbered, opaque, sealed envelopes that
would designate patients to sequences identified with
letters from A to F. The envelopes were prepared, ran-
domly ordered and then numbered by the PI according
to the SNOSE method [24]. This randomization method
allows the concealment of the allocation sequence even
from the person performing the steps for randomization,
once that the sequence results from the shuffling and
numbering of the sealed and opaque envelopes (i.e.,
there is no register of the randomization sequence).
Researchers external to the study (BR and MFST) put
the drugs in opaque plastic mailing bags of identical ap-
pearance, and then sealed and identified them only by
letters corresponding to allocation sequences and the
study periods (e.g. A, 2nd month), allowing blinding of
personnel involved in the treatment of the patients (the
PI and the cardiologists) and in the collection of data
(the PI). These external researchers are the only ones
who know the code of letters for the sequences of treat-
ment. Copy of this allocation list is stored in an opaque
and sealed envelope that will be opened only at the end
of the study, at the time of statistical analysis by the PI.
With this process, besides generating the allocation se-
quence, the PI was be able to enrol participants, assign
them to the intervention and also follow them up with-
out compromising the allocation concealment and the
blinding/masking.
Since every patient would be taking warfarin, we de-
cided that blinding should be kept throughout the trial
and unblinding would not be permitted. In the case of
any emergency patients would be treated accordingly,
knowing that they were taking warfarin.
Patients, however, were not blinded to treatments. The
warfarin tablets from different manufacturers were different
in their appearance, but we decided to keep them in their
original packaging (we just added the external opaque bag
to blind personnel) in order to avoid interfering with their
stability or else with their bioavailability.
Carry-over effect
Since we could not take the patients off warfarin for a
complete washout for ethical reasons, the INR measure-
ments planned were taken only after 3 weeks after the
switch of formulations (Table 2) as a way of ensuring
that the effects of drugs administered in the previous
period would not contaminate the outcomes. This
period is superior to 5 half-lives (warfarin’s half-life: 25
to 60 h [25]), time that is considered enough in pharma-
cokinetics for clearance of drugs from the body [26].
In addition to addressing carry-over in the design of
the trial, we will also use the approach described by
Jones and Kenward to test for carry-over effects in the
statistical analysis stage [27].
Sample size
Sample size calculation was based on the outcome of the
mean INR, which, as described before, was our previous
primary outcome. It was intended to detect a clinically
significant difference of 0.49 in the mean INR, assuming
a significance level of 5 and a 90% power.
Data were inputted in the formula presented as a stat-
istical method for a quantitative outcome [28]. This for-
mula is intended for a parallel trial (independent groups)
and we expected it to result in a super estimation of the
sample size in this trial due to its cross-over design (i.e.
dependent observations) [29].
Standard deviation for the INR inputted in the formula
was 0.34, which was the higher standard deviation
shown for the mean INR of a warfarin formulation in a
previous trial (calculated from a standard error reported)
[9]. These assumptions resulted in a sample size of 11
patients in each group. Thus, if the trial was parallel, we
would need 33 patients for detecting this difference.
Since the trial was a cross-over, we would then probably
need a smaller sample size.
First, we aimed to recruit at least 33 patients complet-
ing the trial. Due to the high rate of subjects not meet-
ing the INR stability criteria in the 1st period we aimed
to recruit 100 patients.
Statistical analysis
We did not plan or conduct any interim analyses. We
will analyze data with the software STATA/IC 14.0 for
Windows. Data will be modelled using a multilevel
mixed-effects linear regression with random intercepts.
We will include terms for: the sequence of administra-
tion of treatments [30]; the time-periods that the treat-
ments were administered [30, 31]; the treatment; the
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carry-over effect and also for the patient [31]. All the ef-
fects will be fixed, except for the patient that will be a
random intercept. We will not use baseline measures as
covariates since we did not take patients out of the drug
(wash out) and thus baseline measures are the result of
different warfarin formulations that patients were taking
before the trial. For all analysis of continuous outcomes
we will present the mean differences and confidence in-
tervals so that it can be shown whether the results are
conclusive or not [32].
For assessing the effects of the other terms besides the
treatment on the outcome, we will use a two-staged pro-
cedure [33], adding these effects to the model and testing
them for significance: if any of them is significant at the
5% level, treatment effects are deemed not equal across
periods and thus we will not pool them together in a
cross-over fashion. Only data from the first treatment
period, in a parallel-like fashion, will be used then [30].
On the other hand, if none of them are significant, these
variables will be dropped from the model and data from
the other periods (2nd, 3rd and 4th months) will also be
considered in the analysis. In the latter, all the following
planned analysis for the outcomes will be performed.
We will not impute missing outcome data. Because
the potential direction and magnitude of biases from
missing data are unpredictable, we decided to analyse
three populations based on their pattern of missing out-
come data. To be maximally conservative, if any of these
analyses demonstrate non-equivalence between warfarin
formulations, we will consider that formulation non-
equivalent (i.e. all three analytic populations are consid-
ered equally). We will present patient baseline character-
istics for each analytic population.
The first analytic population is referred to as “Complete
cases”. This encompasses data from patients that had at
least one valid INR in every treatment period (or ΔINR,
for which at least 2 valid INRs would be necessary).
Another population for analysis is called “First treat-
ment period group” and it is comprised of only the data
of the 1st period for patients with at least one valid INR
or ΔINR in this same period. This population retains the
randomization balance. Including also the data from pa-
tients with high variability in the analysis and consider-
ing this data as a parallel comparison between the
warfarin formulations will help us assess whether the
same conclusions as for the complete cases hold, even if
our initial assumption about confounders in patients
with high INR variability does not.
The last population for analysis is named “modified
ITT” and it is composed of patients with at least one
valid INR or ΔINR in any time period. This would in-
clude all valid data from all patients randomized. Using
the linear mixed model for the cross-over we are able to
include even the incomplete data from patients that did
not complete treatment sequences and account for them
in the analysis. However, since they do not have as much
information as the other patients (i.e. there are no mea-
surements in some periods), they will be consequently
accounted with less weight than the patients that actu-
ally completed the trial.
Discussion
The WARFA trial addresses the therapeutic equivalence
issue of generic warfarin in Brazil in a novel way. Besides
assessing therapeutic equivalence (not bioequivalence) be-
tween the effect of generics and the branded drug, an un-
met need in Brazil, we will also focus on comparing
among generic drugs. Despite not devised to be therapeut-
ically equivalent to each other, generic drugs from differ-
ent manufacturers are commonly switched in the course
of a chronic treatment in Brazil, and thus it is desirable to
evaluate their suitability for this purpose. Our question
may initially be of interest for Brazilians but warfarin is
still used worldwide and we believe that the switch be-
tween many different brands is not a situation restricted
to Brazil. Therefore, we consider that our methods of ap-
proaching this issue will be of interest of a wider audience.
Detecting small differences within generic and
branded drugs motivated us to use a cross-over design.
This design focuses on the analysis of what is called
within-patients differences: the difference between ef-
fects of treatments observed in the same individual,
which acts as its own control. The within-patients esti-
mates of treatment effects ensure balance of confound-
ing factors inherent to patients [34].
Nevertheless, cross-over designs also presents draw-
backs: the sequences to which patients are randomized
differ with respect to their recent exposure to other po-
tentially effective treatments (i.e. the treatment applied
in the previous period). Thus, the trial design alone does
not guarantee comparability between treatments, be-
cause this depends also on the treatment effects being
confined to the period of their administration and
follow-up. When this condition does not hold and the
effect of one treatment contaminates the treatment in
the following period, it causes a carry-over effect [34]. In
our trial, we planned to address carry-over effects in the
design (the timing of the outcome measures) and also in
the analysis of the data (testing for carry-over effects and
analysing data accordingly).
Another challenge of cross-over trials is dealing with
missing data. In conventional analysis, in which subjects
are considered fixed effects (e.g. T-test), a value missing
for a patient in one period of the trial compromises all
the information of that subject. Since there is no within-
patient difference for that individual, the incomplete in-
formation cannot be used for estimation of the treat-
ment effects and is thus discarded. Conversely, mixed
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models that assume random subjects have the advantage
of being able to use the available information even when
data are missing in a cross-over design [31, 34]. For
dealing with the missing data issue, not only we are
using linear mixed models in the analysis, but we also
planned to use different populations, taking advantage
from the 1st period, in order to check whether our as-
sumptions change the conclusions of the trial.
In this article we described some changes from the ori-
ginal protocol in the outcomes. We also had to change the
eligibility criteria in order to recruit more patients. At first,
only nonvalvular AF patients were eligible to the WARFA
trial. However, we decided to include also atrial flutter
(AFL) patients and AF/AFL valvular patients without
mechanical prosthetic valves, i.e. AF/AFL patients with
rheumatic disease or mitral stenosis, because they all re-
ceive anticoagulation with warfarin in the same therapeutic
range as the nonvalvar AF patients [35]. Since we expect
the same effect of warfarin in preventing thromboembolic
events in all these subjects, we do not expect that this deci-
sion will bias our estimates [36]. All the modifications have
been described, were planned up to the statistical analysis
plan stage, i.e. before data analysis and also before unblind-
ing, and we do not expect them to bias our estimates.
Unfortunately, due to time and resources restrictions, we
were not able to couple the WARFA trial with bioequivalence
studies, that would help us compare bioavalabilities to
warfarin results. However, we focused on the more readily ap-
plicable question, of whether there is actual therapeutic
equivalence between the formulations available in Brazil.
Trial status
Patient recruitment and follow-up are already com-
pleted. At the time of submission, we finished the statis-
tical analysis plan and are working on study close out.
Final results are expected by May 2017.
Endnote
1All the limits follow the same ±20% rule. However,
the actual values for the limits differ according to the
scale used (arithmetic or logarithmic) and the kind of
comparison being made (difference or ratio) [6].
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